Edgardo Rivera

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Cost-effectiveness of influenza vaccination in working-age cancer patients
    Elenir B C Avritscher
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2357-64. 2007
  2. ncbi request reprint Clinical model of lifetime cost of treating bladder cancer and associated complications
    Elenir B C Avritscher
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 68:549-53. 2006
  3. ncbi request reprint Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis
    Elenir B C Avritscher
    Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard Unit 196, Houston, TX 77030 4009, USA
    Support Care Cancer 12:531-6. 2004
  4. ncbi request reprint Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients
    Elenir B C Avritscher
    Division of Quantitative Sciences, Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    J Support Oncol 8:242-51. 2010
  5. ncbi request reprint Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1348-54. 2006
  6. doi request reprint Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1455-61. 2008
  7. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
  8. ncbi request reprint Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 8:2-9. 2002
  9. ncbi request reprint Outcomes and cost of deep venous thrombosis among patients with cancer
    Linda S Elting
    Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Arch Intern Med 164:1653-61. 2004
  10. ncbi request reprint Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:2321-6. 2002

Detail Information

Publications52

  1. ncbi request reprint Cost-effectiveness of influenza vaccination in working-age cancer patients
    Elenir B C Avritscher
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2357-64. 2007
    ..In the current study, the authors analyzed the cost-effectiveness of influenza vaccination in working-age (ages 20-64 years) cancer patients...
  2. ncbi request reprint Clinical model of lifetime cost of treating bladder cancer and associated complications
    Elenir B C Avritscher
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 68:549-53. 2006
    ..To estimate the lifetime cost of bladder cancer and the contribution of complications to the total costs...
  3. ncbi request reprint Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis
    Elenir B C Avritscher
    Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard Unit 196, Houston, TX 77030 4009, USA
    Support Care Cancer 12:531-6. 2004
    ....
  4. ncbi request reprint Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients
    Elenir B C Avritscher
    Division of Quantitative Sciences, Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    J Support Oncol 8:242-51. 2010
    ..The cost-utility of palonosetron-based therapy exceeds the $100,000/QALY threshold. Future research incorporating the price structure of all antiemetics following ondansetron's recent patent expiration is needed...
  5. ncbi request reprint Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1348-54. 2006
    ..A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer...
  6. doi request reprint Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1455-61. 2008
    ..The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and more efficacious...
  7. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  8. ncbi request reprint Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 8:2-9. 2002
    ..The benefit was greater on patients with node-negative primary tumors. In patients with stage IV-NED disease, doxorubicin-based chemotherapy should be considered standard treatment after adequate local control is achieved...
  9. ncbi request reprint Outcomes and cost of deep venous thrombosis among patients with cancer
    Linda S Elting
    Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Arch Intern Med 164:1653-61. 2004
    ..Furthermore, the cost of DVT is largely undescribed. We herein report the largest study of DVT in this population to date...
  10. ncbi request reprint Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:2321-6. 2002
    ....
  11. ncbi request reprint Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer
    Edgardo Rivera
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:987-93. 2002
    ..The primary objective of this study was to estimate the objective tumor response rate of orally administered eniluracil and 5-FU in the treatment of anthracycline- and taxane-resistant advanced breast cancer...
  12. ncbi request reprint Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 104:1158-71. 2005
    ..An analysis of prognostic factors for these patients also is presented...
  13. ncbi request reprint Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
    Silwan Chedid
    Department of Breast Medical Oncology, M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Unit 424, Houston, TX, 77030 4095, USA
    Cancer Chemother Pharmacol 57:540-4. 2006
    ..The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies...
  14. ncbi request reprint A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer
    L Johnetta Blakely
    Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5425-31. 2004
    ..The objective of this study was to investigate the safety and the pharmacokinetics in patients with previously treated advanced breast cancer...
  15. ncbi request reprint Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel
    Bita Esmaeli
    Section of Ophthalmology, Division of Pharmacy, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:3619-22. 2006
    ..To determine the incidence and severity of epiphora and canalicular stenosis in patients receiving docetaxel weekly or every 3 weeks...
  16. ncbi request reprint Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ophthalmology 109:1188-91. 2002
    ..To compare the frequency of canalicular stenosis as a side effect of weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer...
  17. doi request reprint Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer
    Banu Arun
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Prev Res (Phila) 5:276-82. 2012
    ..Anastrozole is currently being studied as a prevention agent in a large phase III trial and our results provide support for continued evaluation of IGFBP-1 as a surrogate endpoint biomarker in prospective breast chemoprevention studies...
  18. ncbi request reprint Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3249-54. 2003
    ..We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer...
  19. ncbi request reprint Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cytokine 25:94-102. 2004
    ..The objective of this study was to assess changes in plasma levels of interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-12, and TNF-alpha during chemotherapy and to correlate these changes with musculoskeletal symptoms...
  20. ncbi request reprint Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer
    Lajos Pusztai
    Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3454-61. 2003
    ..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)...
  21. pmc A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2378-84. 2012
    ..Inhibition of mammalian target of rapamycin with everolimus may improve the efficacy of taxanes. Everolimus and docetaxel are both metabolized by CYP3A4, which could result in a pharmacokinetic (PK) interaction...
  22. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
    Eva Thomas
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 25:3399-406. 2007
    ..This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy...
  23. ncbi request reprint Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies
    Edgardo Rivera
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 7:33-41. 2006
    ..Many oncologists are aware of this trend toward the more intensive treatment of patients with cancer and take proactive steps to minimize the risk of myelosuppression and its complications...
  24. doi request reprint Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options
    Edgardo Rivera
    The Methodist Hospital Weill Cornell University, Houston, Texas, USA
    Breast J 16:252-63. 2010
    ..Further clinical evaluation of this agent in patients with drug-resistant breast cancer and in specific patient subsets is warranted...
  25. doi request reprint A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030 4009, USA
    Cancer 116:1440-5. 2010
    ..Orally administered UFT and leucovorin provided higher peak plasma concentrations of 5-FU and prolonged therapeutic 5-FU concentrations compared with continuous infusion of 5-FU...
  26. ncbi request reprint Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:682-91. 2005
    ....
  27. ncbi request reprint Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 10:1943-8. 2004
    ....
  28. pmc First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study
    Edgardo Rivera
    University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 5:R114-20. 2003
    ..This study was designed to validate an earlier published study based on a retrospective data analysis from a prospective randomized clinical trial...
  29. ncbi request reprint Liposomal anthracyclines in metastatic breast cancer: clinical update
    Edgardo Rivera
    Department of Breast Medical Oncology, Division of Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Oncologist 8:3-9. 2003
    ....
  30. ncbi request reprint A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
    Cancer 98:900-7. 2003
    ..The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline-resistant and taxane-resistant, metastatic breast carcinoma...
  31. doi request reprint Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors
    Edgardo Rivera
    The Methodist Hospital Weill Cornell University, Houston, TX 77030, USA
    Oncologist 13:1207-23. 2008
    ..This review discusses the challenges of MDR and the data that support the use of epothilones in this setting, focusing on ixabepilone...
  32. pmc Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
    Edgardo Rivera
    The Methodist Hospital Weill Cornell University, SM701, Houston, TX 77030, USA
    Breast Cancer Res 12:S2. 2010
    ..The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting...
  33. ncbi request reprint Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials
    Banu Arun
    Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4943-8. 2007
    ..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known...
  34. doi request reprint Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes
    Edgardo Rivera
    Breast Medical Oncology Section, The Methodist Hospital Weill Cornell University, Houston, Texas 77030, USA
    Am J Clin Oncol 33:176-85. 2010
    ..Improved treatment strategies and further evaluation of newer agents may reduce the current burden of treatment-resistant or treatment-refractory MBC...
  35. ncbi request reprint Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors
    Karen Basen-Engquist
    The University of Texas M D Anderson Cancer Center, USA
    Patient Educ Couns 64:225-34. 2006
    ..The effect of the intervention on physical performance, quality of life, and physical activity are reported...
  36. ncbi request reprint A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer
    Sharon H Giordano
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3360-8. 2002
    ..This Phase II study was designed to determine the efficacy and toxicity of combination doxorubicin and paclitaxel as front-line treatment for metastatic breast cancer...
  37. doi request reprint Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases
    Karen Eckmann
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Oncol Pharm Pract 20:120-9. 2014
    ..Limited clinical data are available regarding the safety of docetaxel in metastatic breast cancer patients with liver dysfunction...
  38. ncbi request reprint Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors
    Linda S Elting
    The Section of Health Services Research, Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1541-50. 2003
    ..Another goal was to estimate the impact of depth and duration of thrombocytopenia on the cost of thrombocytopenia...
  39. ncbi request reprint Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Chemother Pharmacol 49:299-302. 2002
    ..We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil...
  40. ncbi request reprint Docetaxel secretion in tears: association with lacrimal drainage obstruction
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, Box 443, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Ophthalmol 120:1180-2. 2002
    ..To test the hypothesis that docetaxel may be secreted in tears after intravenous infusion...
  41. ncbi request reprint Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1073-9. 2002
    ..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer...
  42. ncbi request reprint Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
    Daniel J Booser
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, Texas 77030 4095, USA
    Cancer Chemother Pharmacol 50:6-8. 2002
    ..L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer...
  43. ncbi request reprint Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis
    Kadri Altundag
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 110:2640-7. 2007
    ..Several risk factors for CNS metastases have been reported. The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases...
  44. ncbi request reprint Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients
    Carmen P Escalante
    Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 437, Houston, TX 77030, USA
    Support Care Cancer 12:657-62. 2004
    ..The objectives were to determine the success of outpatient treatment of low-risk febrile neutropenia, to identify factors predicting outpatient failure, and to determine mortality related to the febrile episode...
  45. ncbi request reprint Current status of liposomal anthracycline therapy in metastatic breast cancer
    Edgardo Rivera
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0424, Houston, TX 77030, USA
    Clin Breast Cancer 4:S76-83. 2003
    ....
  46. ncbi request reprint Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 0056, USA
    Cancer 98:222-8. 2003
    ..To the authors' knowledge, the current study is the first large prospective validation of a risk model in patients with early-stage breast carcinoma...
  47. ncbi request reprint The role of statins in cancer therapy
    Katja Hindler
    Division of Cardiovascular Anesthesiology, the Texas Heart Institute at St Luke s Episcopal Hospital, 6720 Bertner Avenue, Houston, Texas 77030, USA
    Oncologist 11:306-15. 2006
    ..The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed...
  48. ncbi request reprint Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy
    Bita Esmaeli
    Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:504-7. 2003
    ..The current study was conducted to report the severity and management of canalicular and nasolacrimal duct stenosis as a side effect of docetaxel therapy and to report the outcomes of surgical intervention for this condition...
  49. ncbi request reprint Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1038-44. 2002
    ..This Phase I study examines the toxicity profile, maximum tolerated dose (MTD), and pharmacokinetics of ABI-007...
  50. ncbi request reprint Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
    David S Alberts
    The Arizona Cancer Center, Tucson, AZ, USA
    Semin Oncol 31:53-90. 2004
    ....
  51. ncbi request reprint Factors associated with participation in breast cancer treatment clinical trials
    Nancy E Avis
    Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    J Clin Oncol 24:1860-7. 2006
    ..It is well established that recruitment to clinical trials (CTs) is difficult and time consuming. This article reports on factors related to CT participation among women who were invited to participate in a CT for breast cancer...
  52. ncbi request reprint Expressive writing as a presurgical stress management intervention for breast cancer patients
    Janet S de Moor
    Division of Health Behavior and Health Promotion, The Ohio State University College of Public Health, Columbus, OH 43210, USA
    J Soc Integr Oncol 6:59-66. 2008
    ..EW was not broadly effective as a stress management intervention for women with breast cancer. These data do not support the use of EW as a presurgical mind-body complementary medicine program for this population...